Persistence of antibody response following a booster dose of Hib-MenC-TT glycoconjugate vaccine to five years: a follow-up study.
BACKGROUND: Antibodies against Haemophilus influenzae type b (Hib) and serogroup C Neisseria meningitidis (MenC) persist better to 3½ years of age after a 12-month booster dose of a combination Hib-MenC glycoconjugate vaccine (Hib-MenC-TT) in children primed in infancy with Hib-MenC-TT and diphther...
প্রধান লেখক: | Khatami, A, Snape, MD, Wysocki, J, John, T, Westcar, S, Mesaros, N, Peddiraju, K, Boutriau, D, Yu, L, Pollard, A |
---|---|
বিন্যাস: | Journal article |
ভাষা: | English |
প্রকাশিত: |
2012
|
অনুরূপ উপাদানগুলি
অনুরূপ উপাদানগুলি
-
A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial
অনুযায়ী: Pace, D, অন্যান্য
প্রকাশিত: (2008) -
A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial.
অনুযায়ী: Pace, D, অন্যান্য
প্রকাশিত: (2008) -
Phase II study of a three-dose primary vaccination course of DTPa-IPV/Hib-MenC-TT followed by a 12-month Hib-MenC-TT booster in healthy infants.
অনুযায়ী: Khatami, A, অন্যান্য
প্রকাশিত: (2013) -
Persistence of immunity following a booster dose of Haemophilus influenzae type B-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial.
অনুযায়ী: Khatami, A, অন্যান্য
প্রকাশিত: (2011) -
Bactericidal antibodies against hypervirulent Neisseria meningitidis C field strains following MenC-CRM or MenACWY-CRM priming and MenACWY-CRM booster in children
অনুযায়ী: Marzia Monica Giuliani, অন্যান্য
প্রকাশিত: (2021-05-01)